Pluristem Therapeutics, Inc., a bio-therapeutics company, engages in the production, research, and development of placental-derived adherent stromal cells (ASCs). The company also involves in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic, and autoimmune disorders. It develops a pipeline of products that are derived from the human placenta, a non-controversial, non-embryonic, adult stem cell source. These placental adherent stromal cells (ASCs) are expanded in the companyÂ’s proprietary PluriXTM three-dimensional bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. The companyÂ’s principal product in development includes PLX-PAD for people suffering from peripheral artery disease. Its products in development also include PLX-IBD, which targets inflammatory bowel disease; PLX-MS, targeting multiple sclerosis; PLX-BMT that targets the global shortfall of matched tissue for bone marrow transplantation (BMT) by enhancing the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; and PLX-STROKE, targeting ischemic stroke. The company, formerly known as Pluristem Life Systems, Inc., was founded in 2001 and is based in Haifa, Israe
$1.36 (03/18/09)
